.svg){kind=logo}
Better Patient Outcomes with Epic Language Access Integration
Learn how to improve health outcomes and ensure compliance for individuals with Limited English Proficiency (LEP) with direct language access integration to the Epic Electronic Health Record (EHR) system.
Case Study: Multilingual Retail Marketing
New AI Content Creation Solutions for a Sports and Apparel Giant
Human Expertise Blended With Powerful AI
Lionbridge Aurora AI™ is an AI-first global content platform that increases your multilingual content creation and expands your audience with culturally relevant, hyper-personalized content.
- RESOURCES
With First Patient In (FPI) approaching, Clinical Outcome Assessment (COA) localization can quickly become part of the study start-up critical path. What may appear to be a relatively straightforward translation requirement can entail licensing, assessment of existing translations, linguistic validation (LV), instrument-developer approvals, and electronic clinical outcome assessment (eCOA) implementation across multiple countries and languages.
Twelve weeks may be sufficient time, but this depends heavily on:
- Instruments involved
- Pre-existing assets
- Identification of early key dependencies
An established instrument with validated translations available in the required languages presents a very different scenario from several newly licensed instruments requiring new LV and electronic implementation across many markets. For study teams, the priority should be to establish the complete localization pathway as early as possible and identify activities most likely to affect study readiness.
Localization Planning Starts Before Translation
The localization timeline does not begin when the first translation is assigned. Before Clinical Outcome Assessment (COA) translation requirements can be confirmed, the study team needs a clear understanding of the instruments, versions, countries, and modes of administration included in the study. These questions should be addressed early:
- Which COAs and source versions will be used?
- Who owns the instruments and what licensing permissions are required?
- Which languages and country-specific variants are needed?
- Do validated translations already exist for the required versions?
- Can those translations be reused, or will adaptation or additional validation be required?
- Will the assessments be administered electronically?
- Are there specific requirements from the instrument developer or copyright holder for translation or eCOA migration?
Resolving these questions early can reveal dependencies that may otherwise only become visible once localization is already underway.
Consider what already exists
Launching new clinical outcome assessment localization should not automatically be the first step when a language requirement is identified. Existing translations may be available from instrument developers, previous studies, translation libraries, or other approved sources.
Their suitability, however, must be established. An existing clinical trial translation may relate to a previous source version, have been developed for a different country, lack sufficient validation documentation, or be subject to licensing restrictions. In other cases, only limited changes may have been made to the source instrument, making adaptation or targeted linguistic work more appropriate than a completely new translation. A structured review of existing assets can help determine:
- Source and translation version alignment
- Target country and language variant
- Provenance and validation history
- Modifications made since validation
- Licensing and reuse permissions
- Suitability for the planned mode of administration
This assessment can avoid unnecessary duplication while ensuring that reuse decisions remain appropriately documented.
Consider the Complete Linguistic Validation Pathway for Clinical Outcome Assessment Localization
Where new clinical outcome assessment localization is required, timelines should reflect the full LV methodology, rather than translation alone. Depending on the instrument, intended population, and agreed methodology, the process may include:
- Forward translation
- Reconciliation
- Single or dual back translation
- Clinician review
- Cognitive Debriefing
- Developer Review
- Proofreading
- Final documentation
Some activities also introduce dependencies that aren’t entirely within the localization team's control, such as instrument developer reviews and approvals. For this reason, compressed schedules should be evaluated against the complete workflow and its dependencies, rather than solely against the time required to produce translated text.
Include eCOA Implementation in the Critical Path
Approval of the final translation may not represent the end of clinical outcome assessment localization activity. When an assessment is administered electronically, approved content still needs to be transferred to the eCOA platform, configured, tested, and reviewed in its final context. Depending on the implementation and instrument requirements, activities may include:
- Transfer and configuration of approved multilingual content
- Generation of localized screenshots
- Linguistic screenshot review
- Correction and regeneration of affected screens
- Functional or user acceptance testing
- Instrument-developer or copyright-holder approval where required
Planning these activities alongside LV, rather than addressing them only after translation approval, can provide a more realistic view of the study's overall readiness.
Assess Readiness Across the Full Clinical Outcome Assessment Localization Pathways
Rather than asking whether twelve weeks is universally sufficient for clinical outcome assessment localization, study teams can obtain a more useful answer by reviewing readiness across five connected areas:
Instrument readiness → Licensing → Translation and LV → eCOA implementation → Final approval and deployment
The critical path will differ from study to study. Identifying it early allows teams to focus resources on genuine dependencies, determine which activities can appropriately run in parallel, and escalate potential blockers before they affect deployment.
COA localization is best incorporated into study start-up planning rather than treated as a downstream translation task. Earlier planning does not necessarily require clinical outcome assessment localization activities to begin sooner. It provides the visibility needed to understand what must happen, in what sequence, and where delays are most likely to occur before the first patient completes the assessment.
Get in touch
Need assistance with your linguistic validation process or regulatory compliance language strategy? Looking for clinical trial translation services that bring decades of expertise and innovative AI tools? Let’s get in touch.
